title: Visual symptoms after optic neuritis. Results from the Optic Neuritis Treatment Trial.
abstract: As part of the Optic Neuritis Treatment Trial, vision-specific quality-of-life data were collected on the patients at their 6-month visits. The purpose of this study was to determine the types of visual tasks in day-to-day living in which patients have difficulty and to compare the patients' subjective assessment of visual impairment with measurements of visual acuity, contrast sensitivity, mean deviation, and color vision. The questionnaire was completed by 382 (87%) of the 438 patients who had 6-month study visits. Associations between ophthalmic test scores and self-reported vision were examined using both a summary problem index and selected individual items. Although a substantial percentage of the patients (63%) indicated that vision had not recovered to normal in the affected eye, the reported visual deficits generally were mild. For most of the visual tasks of daily living, patients reported little or no problem. Among the 215 patients who perceived their vision at 6 months to be somewhat or much worse than it was before optic neuritis, 20% had normal results on none of the four visual function tests, 14% had normal results on one of the four tests, 23% had two of four, 23% had three of four, and 20% had normal results on all four. Reported visual symptoms 6 months after optic neuritis generally were mild. When patients were symptomatic, the four visual function tests often did not detect abnormality. This finding supports previous reports that visual deficits are frequently perceived even when vision testing is normal.
authors.affiliation: Biostatistics Center, George Washington University, USA.
authors.forename: P A
authors.initials: PA
authors.lastname: Cleary
authors.forename: R W
authors.initials: RW
authors.lastname: Beck
authors.forename: L B
authors.initials: LB
authors.lastname: Bourque
authors.forename: J C
authors.initials: JC
authors.lastname: Backlund
authors.forename: P H
authors.initials: PH
authors.lastname: Miskala
mesh_terms: D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008776:Methylprednisolone Hemisuccinate / Q000008:administration & dosage / Q000627:therapeutic use; D009902:Optic Neuritis / Q000188:drug therapy / Q000503:physiopathology*; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D011788:Quality of Life; D012189:Retrospective Studies; D012650:Self Disclosure; D011795:Surveys and Questionnaires; D014786:Vision Disorders / Q000188:drug therapy / Q000503:physiopathology*; D014785:Vision, Ocular / Q000502:physiology
chemical_list: D005938:Glucocorticoids; D008776:Methylprednisolone Hemisuccinate; D011241:Prednisone